Medication Monitor



Generic Name (Trade Name—Company)
Notes
April 1, 2011

Imiquimod

(Zyclara—Graceway)
Treatment of external genital and perianal warts

Uses:

Treatment of external genital and perianal warts in patients 12 years of age and older

Approval of Zyclara was based on data from two Phase III, double-blind studies that evaluated the complete clearance of warts across several anatomical locations with imiquimod 3.75% cream. Approximately 28.3% of patients using once-daily imiquimod cream for up to 8 weeks had complete clearance of all warts compared with 9.4% of those given placebo cream. In addition, only 15% of patients treated with imiquimod experienced a recurrence within 12 weeks. The product was originally approved for the treatment of actinic keratoses of the face or balding scalp in immunocompetent patients.